Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer.
[esophageal squamous cell carcinoma]
The
aim
of
this
study
was
to
evaluate
the
efficacy
and
tolerability
of
the
combination
of
paclitaxel
and
nedaplatin
in
patients
with
advanced
esophageal
cancer
.
Patients
(
n
=
310
)
with
recurrent
or
metastatic
esophageal
squamous
cell
carcinoma
,
who
had
a
maximum
of
one
previous
chemotherapy
regimen
,
were
enrolled
in
this
study
.
All
patients
had
bidimensionally
measurable
disease
.
Patients
received
175
 
mg
/
m
of
paclitaxel
over
a
3
 
h
infusion
,
followed
by
nedaplatin
80
 
mg
/
m
in
a
1
 
h
infusion
on
day
1
every
3
weeks
for
up
to
6
treatment
cycles
.
The
overall
response
rate
was
47
.
7
%
,
with
complete
and
partial
response
rates
of
6
.
1
and
41
.
7
%
,
respectively
.
The
median
time
to
progression
for
all
patients
was
6
.
8
months
(
95
%
confidence
interval
,
6
.
2
-
7
.
4
months
)
and
the
3
-
year
disease-free
survival
probability
was
3
(
15
.
8
%
)
.
The
major
toxicity
observed
was
cumulative
neutropenia
,
with
29
%
patients
developing
grade
4
toxicity
.
There
was
no
treatment-related
death
.
The
most
common
nonhematologic
toxicity
encountered
with
this
regimen
was
pain
and
cumulative
peripheral
neuropathy
,
with
26
%
patients
experiencing
grade
2
or
3
toxicity
.
The
combination
of
paclitaxel
and
nedaplatin
shows
significant
antitumor
activity
and
a
favorable
toxicity
profile
in
patients
with
metastatic
carcinoma
of
esophageal
cancer
.
Diseases
Validation
Diseases presenting
"common nonhematologic toxicity"
symptom
esophageal squamous cell carcinoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
